The truth is until 2591 hits the clinic it's pretty much worthless. I think BPs valuation is pretty fair as failure in retts will severely impact the company. That's really the only important catalyst at the moment.
Unfortunately we have a small, unprofitable pharma leading our trial with a delay to boot. I'm not surprised people haven't jumped in to buy this stock just yet as there's at least 12 months before you need to buy and hold and put your investment in the line as we wait for Ph3 results.
Bell Porter Review, page-9
-
- There are more pages in this discussion • 65 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.14 |
Change
-0.130(0.85%) |
Mkt cap ! $1.935B | |||
| Open | High | Low | Value | Volume |
| $15.38 | $15.47 | $14.93 | $7.335M | 485.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7079 | $15.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.17 | 3189 | 3 |
View Market Depth
| Last trade - 16.10pm 30/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |